---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-033055"
form_type: "8-K"
ticker: "TGTX"
cik: "0001001316"
company_name: "TG THERAPEUTICS, INC."
filed_at: "2024-11-04T23:59:59+00:00"
generated_at: "2026-05-30T05:45:17.353854+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# TG Therapeutics Q3 BRIUMVI revenue $83.3M, raises FY2024 guidance to $300-$305M

## Summary
- BRIUMVI Q3 U.S. net sales $83.3M, up 15% QoQ and 230% YoY; full-year target raised to $300-$305M.
- Net income $3.9M in Q3 vs $113.9M a year ago (prior period included $140M upfront payment); cash $341M.
- Phase 1 trial of subcutaneous ublituximab initiated; FDA cleared IND for azer-cel in progressive MS.
- Secured FUJIFILM Diosynth as secondary U.S. manufacturer of BRIUMVI.
- Five-year ECTRIMS data: 92% of patients free from disability progression; annualized relapse rate 0.02.

## SEC filing metadata
- accession: 0001437749-24-033055
- form_type: 8-K
- ticker: TGTX
- cik: 0001001316
- company_name: TG THERAPEUTICS, INC.
- filed_at: 2024-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001316/000143774924033055/0001437749-24-033055-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001316/000143774924033055/tgtx20241103_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-033055
- JSON: https://secwatch.observer/filing/0001437749-24-033055.json
- Plain text: https://secwatch.observer/filing/0001437749-24-033055.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.